RxDoctor Payments Data

James Miller, MD

Interventional Cardiology · Virginia Beach, VANPI 1023067733

Payments from drug & device makers

$1,874in general payments, 2019–2025

Across 67 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$302
  • Biotronik Inc.$236
  • Abbott$216
  • Amgen$180
  • Boehringer Ingelheim$153
  • Kiniksa Pharmaceuticals, Ltd.$125
  • plus $663 from 12 others

What the payments were for

  • Food & beverage$1,874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,874 in reported general payments places this provider in the 25th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$292,329
Medicare patients
1,723
Services billed
3,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$91,311
XareltoRivaroxaban15$26,395
Repatha SureclickEvolocumab25$23,116
JardianceEmpagliflozin13$18,686
EntrestoSacubitril/Valsartan15$16,986
FarxigaDapagliflozin Propanediol17$14,992
Ezetimibe56$1,663
Metoprolol Succinate113$1,432
Atorvastatin Calcium104$1,115
Rosuvastatin Calcium80$827
Carvedilol62$484
Furosemide64$326
Lisinopril46$324
Isosorbide Mononitrate ErIsosorbide Mononitrate25$290
Losartan Potassium41$259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$91,31163 claims
Johnson & JohnsonXarelto$52$26,39515 claims
Boehringer IngelheimJardiance$153$18,68613 claims
NovartisEntresto$83$16,98615 claims
AstraZenecaFarxiga$96$14,99217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →